Clinical Trial Update: Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the use of liquid biopsy to monitor resistance to EGFR TKIs, including osimertinib, in EGFR-mutant non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN